Literature DB >> 25988249

[Survival rate of patients with stomach cancer in Peru, 2009-2010].

Carlos Alvarado Tolentino1, Diego Venegas Ojeda2.   

Abstract

OBJECTIVE: Determine the survival rate of patients diagnosed with stomach cancer in 2009-2010 in Peru.
METHODS: A retrospective cohort study was conducted of patients diagnosed with stomach cancer registered in the National Epidemiological Surveillance System (SNVE) of the Directorate General of Epidemiology (DGE) and the Register of Vital Statistics (RHV) of the General Office of Statistics and Information (OGEI) for the years 2009-2010.
RESULTS: 3 568 patients of the SNVE were included; 51.5% were men and 48.5% were women; the average age was 63.9 years; 60.07% were 60 years old or older. It was found that 33.6% had intestinal type adenocarcinoma, 18.7% had diffuse type carcinoma, and 4.1% had primary gastric lymphoma. The overall survival rate was 29.7 ± 0.8 months and was better for those under 60 years (P = 0.034), for women (P = 0.014) and for intestinal type adenocarcinoma (P< 0.001). There was no difference (P = 0.713) between the survival rate of gastric lymphomas and adenocarcinomas. In order to evaluate mortality, 6 069 patient records from the RHV were included; national mortality was 10.3 per 100 000 population; the regions with the highest mortality were Huánuco, Huancavelica, and Junín.
CONCLUSIONS: The general survival rate was 29.7 ± 0.8 months; women, those under 60 years, and patients with intestinal type adenocarcinoma had better survival rates. The highest mortality from stomach cancer is concentrated in the poorest regions of Peru, where it is probable that living conditions facilitate the high communicability of Helicobacter pylori.

Entities:  

Mesh:

Year:  2015        PMID: 25988249

Source DB:  PubMed          Journal:  Rev Panam Salud Publica        ISSN: 1020-4989


  1 in total

Review 1.  Current approaches to gastric cancer in Peru and Mexico.

Authors:  Erlan Santos
Journal:  Transl Gastroenterol Hepatol       Date:  2017-05-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.